# Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

> **NCT03529825** · EARLY_PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 26 (actual)

## Conditions studied

- Microbial Colonization

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT03529825
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2020-10-19
- **Final completion:** 2021-09-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529825, "Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03529825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*